University of Alabama at Birmingham
O'Neal Comprehensive Cancer Center
Birmingham, AL
Filters
Save & Share
Clear Filters
Diagnosis
Purpose of Trial
Filter and find trials based on their purpose.
Risk Level
Enter this patient's risk level (IPSS-R / IPSS-M).
Accepting patients
NTX-301
A Phase 1 Study of NTX-301, an Oral DNMT1 Inhibitor, in Patients With MDS and AML
Learn more- DNMT1 Inhibitor
- Phase 1
Accepting patients
LIMBER
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms
Learn more- BET Inhibitor
- JAK1 Inhibitor
- JAK2 Inhibitor
- Phase 1
Accepting patients
VIP943
An Open-label, Multicenter Phase 1 Study to Characterize Safety, Tolerability, Preliminary Antitumor Activity, Pharmacokinetics, and Pharmacodynamics of VIP943 Monotherapy in Subjects With Advanced CD123+ Hematologic Malignancies
Learn more- Antibody Drug Conjugate (ADC)
- Kinesin Spindle Protein (KSP) Inhibitor
- CD123
- Phase 1
Not yet accepting
2 Step ATG
Phase II Clinical Trial of 2 Step ATG Combined With Tacrolimus and Mini Methotrexate for Prevention of Acute GVHD Post Myeloablative Allogeneic Stem Cell Transplant
Learn more- Phase 2
Not yet accepting
GVHD Prevention Using CliniMACS
Feasibility Study of CD34 Selection for GVHD Prophylaxis Using the Automated CliniMACS
Learn more- CD34
- Phase 1
Not yet accepting
ATG Dosing for GVHD Prevention
Phase II Clinical Trial of 2 Step ATG Combined With Tacrolimus and Mini Methotrexate for Prevention of Acute GVHD Post Reduced Intensity Allogeneic Stem Cell Transplant
Learn more- Phase 2